(Q61907332)
Statements
An Open-label, Multi-center, Phase 2 Study of Denosumab in Subjects With Giant Cell Rich Tumors of Bone (English)
0 references
18 June 2018
0 references
June 2021
0 references
60
0 references
18 year
0 references